Fungal endocarditis complicating treatment of prosthetic valve bacterial endocarditis: value of prophylactic oral nystatin.
We describe two patients in whom fungal endocarditis occurred during antibiotic therapy for prosthetic valve bacterial endocarditis. Successful management of both patients was eventually achieved with antifungal therapy and replacement of the prosthetic valves. These cases and review of the literature suggest that (1) high-dose antibacterial therapy predisposes to fungal endocarditis; (2) during prolonged antibiotic therapy in patients predisposed to endocarditis, clinicians should consider the use of oral nystatin as prophylaxis against fungemia and possible fungal endocarditis; and (3) early replacement of prosthetic valves infected with fungi is indicated because chemotherapy alone is predictably inadequate to effect a cure.
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
C R
CR
Gregg
Z A
ZA
McGee
S J
SJ
Bodner
D A
DA
Killen
G C
GC
Friesinger
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002177:Candidiasis / Q000209:etiology* / Q000517:prevention & control; D004696:Endocarditis / Q000209:etiology* / Q000517:prevention & control; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D009761:Nystatin